bioRxivBiochemistryPreprint
A First-in-class, Highly Selective and Cell-active AllostericInhibitor of Protein Arginine Methyltransferase 6 (PRMT6)
Y. Shen, F. Li, M. Szewczyk, L. Halabelian, I. Chau, M. S. Eram, C. Dela Sena, K.-S. Park, F. Meng, H. Chen, H. Zeng, D. McLeod, C. A. Zepeda-Velazquez, R. M. Campbell, M. M. Mader, B. M. Watson, M. Schapira, C. H. Arrowsmith, R. Al-Awar, D. Barsyte-Lovejoy, H. U. Kaniskan, P. J. Brown, M. Vedadi, J. Jin
Abstract
PRMT6 catalyzes monomethylation and asymmetric dimethylation of arginine residues in various proteins, plays important roles in biological processes and is associated with multiple cancers. While there are several reported PRMT6 inhibitors, a highly selective PRMT6 inhibitor has not been reported to date. Furthermore, allosteric inhibitors of protein methyltransferases are rare. Here we report the discovery and characterization of a first-in-class, highly selective allosteric inhibitor of PRMT6, SGC6870. SGC6870 is a potent PRMT6 inhibitor (IC50 = 77 {+/-} 6 nM) with outstanding selectivity for PRMT6 over a broad panel of other methyltransferases and non-epigenetic targets. Notably, the crystal structure of the PRMT6-SGC6870 complex and kinetic studies revealed SGC6870 binds a unique, induced allosteric pocket. Additionally, SGC6870 engages PRMT6 and potently inhibits its methyltransferase activity in cells. Moreover, SGC6870s enantiomer, SGC6870N, is inactive against PRMT6 and can be utilized as a negative control. Collectively, SGC6870 is a well-characterized PRMT6 chemical probe and valuable tool for further investigating PRMT6 functions in health and disease.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of a Potent and Dual-Selective Bisubstrate Inhibitor for Protein Arginine Methyltransferase 4/5
A. A. Al-Hamashi, D. Chen, … R. Huang·bioRxiv·Sep 5, 2020
- Rational Design and Synthesis of Selective PRMT4 Inhibitors: a New Chemotype for Development of Cancer Therapeutics
M. Sutherland, A. Li, … V. Santhakumar·bioRxiv·Nov 17, 2020
- Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response
M. M. Szewczyk, Y. Ishikawa, … D. Barsyte-Lovejoy·bioRxiv·Mar 15, 2019
- A chemical biology toolbox to investigate in-cell target engagement and specificity of PRMT5-inhibitors
Elisabeth M. Rothweiler, Jakub Stefaniak, … K. Huber·bioRxiv·Jan 20, 2022
- Transcriptomic and proteomic regulation through abundant, dynamic, and independent arginine methylation by Type I and Type II PRMTs
Maxim I. Maron, Stephanie M. Lehman, … David Shechter·iSciencePeer-reviewed·Aug 11, 2021
- Discovery of a first-in-class inhibitor of the PRMT5-substrate adaptor interaction
D. C. McKinney, B. J. McMillan, … A. Ianari·bioRxiv·Feb 3, 2021